mavoglurant + levodopa

Mavoglurant (AFQ056) is a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), developed as an experimental treatment for neurological disorders. Levodopa is a prodrug of dopamine, widely used in Parkinson's disease to supplement deficient dopamine levels in the brain. The combination of mavoglurant and levodopa has been investigated primarily for the management of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Mavoglurant acts by inhibiting mGluR5, potentially modulating abnormal glutamatergic signaling associated with LID, while levodopa restores dopaminergic activity to alleviate motor symptoms. Clinical trials have shown inconsistent efficacy for this combination in reducing LID severity[1][2][4][7]. Mavoglurant was originally developed by Novartis and later acquired by Stalicla for further development[5].

Other names

mavoglurant + levodopaAFQ056 + levodopa